scholarly journals Correction to: Micropulse trans-scleral diode laser cyclophotocoagulation in refractory glaucoma: an initial experience in Indian eyes

2021 ◽  
Author(s):  
Murali Ariga ◽  
Nivean ◽  
Pratheeba Devi Nivean ◽  
V. G. Madanagopalan ◽  
Sujatha Mohan
Keyword(s):  
Diode Laser ◽  
Initial Experience ◽  
Refractory Glaucoma ◽  
Diode Laser Cyclophotocoagulation

Micropulse trans-scleral diode laser cyclophotocoagulation in refractory glaucoma: an initial experience in Indian eyes

2021 ◽  
Author(s):  
Murali Ariga ◽  
Nivean ◽  
Pratheeba Devi Nivean ◽  
V. G. Madanagopalan ◽  
Sujatha Mohan
Keyword(s):  
Visual Acuity ◽  
Diode Laser ◽  
Open Angle Glaucoma ◽  
Small Sample Size ◽  
Small Sample ◽  
Initial Experience ◽  
Refractory Glaucoma ◽  
Surgical Success ◽  
Topical Medications ◽  
Diode Laser Cyclophotocoagulation

Abstract Purpose To evaluate the efficacy and safety of micro-pulse trans-scleral diode laser cyclophotocoagulation (MP-TSCPC) in Indian eyes with refractory glaucoma. Methods A prospective interventional short-term study was carried out with relatively small sample size of 55 eyes with refractory glaucoma. All eyes had visual acuity (VA) and intraocular pressure (IOP) measurements at baseline, 1 week (1w), 1 month (1 m) and 3 months (3 m). A single surgeon treated all eyes with recommended MP-TSCPC treatment settings. Surgical success was defined as achieving an IOP between 8–21 mmHg or achieving > 20% IOP reduction. Results The age of participants was 56.98 ± 15.74 years. Our study had more number of males. VA (in logMAR) at baseline was 1.38 ± 0.99. VA was 1.43 ± 0.93 at 1w, 1.47 ± 0.94 at 1 m and 1.47 ± 0.96 at 3 m (p > 0.05 for all). IOP (in mmHg) at baseline was 30.38 ± 10.70. IOP was 15.72 ± 6.85 at 1w, 16.98 ± 8.72 at 1 m and 17.60 ± 8.40 at 3 m (p < 0.001 for all). At 3 m, 49 (89.1%) eyes had surgical success. Surgical success was lesser in primary open angle glaucoma (p = 0.03). IOP at baseline showed significant correlation with percentage reduction in IOP at each review (p < 0.05). Use of glaucoma medication reduced from 2.94 ± 0.98 to 2.01 ± 1.16 at 3 m (p < 0.001). At 3 m, hypotony was noted in 4 (7.3%) eyes and reduction in visual acuity was seen in 15 (27.3%) eyes. Conclusion Initial experience in Indian eyes has shown that MP-TSCPC is safe and effective for refractory glaucoma. Patients can expect significant IOP lowering along with reduction in number of topical medications required for control of IOP.

Micropulse Transscleral Diode Laser Cyclophotocoagulation in Refractory Glaucoma

2019 ◽  
Vol 2 (6) ◽  
pp. 402-412 ◽  
Author(s):  
Giancarlo A. Garcia ◽  
Christine V. Nguyen ◽  
Aleksandr Yelenskiy ◽  
Goichi Akiyama ◽  
Brett McKnight ◽  
...  
Keyword(s):  
Diode Laser ◽  
Refractory Glaucoma ◽  
Diode Laser Cyclophotocoagulation

Transscleral diode laser cyclophotocoagulation for refractory glaucoma secondary to juvenile idiopathic arthritis: a short term follow-up

2012 ◽  
Vol 33 (4) ◽  
pp. 409-413 ◽  
Author(s):  
Anna I. Dastiridou ◽  
Sofia Androudi ◽  
Anna Praidou ◽  
Periklis Brazitikos ◽  
Catherine G. Brozou ◽  
...  
Keyword(s):  
Juvenile Idiopathic Arthritis ◽  
Diode Laser ◽  
Refractory Glaucoma ◽  
Short Term ◽  
Diode Laser Cyclophotocoagulation

Micropulse transscleral cyclophotocoagulation using a standard protocol in patients with refractory glaucoma naive of cyclodestruction

2019 ◽  
pp. 112067211987758 ◽  
Author(s):  
Soufiane Souissi ◽  
Christophe Baudouin ◽  
Antoine Labbé ◽  
Pascale Hamard
Keyword(s):  
Intraocular Pressure ◽  
Diode Laser ◽  
Glaucoma Surgery ◽  
Refractory Glaucoma ◽  
Corrected Visual Acuity ◽  
Pressure Lowering ◽  
Transscleral Cyclophotocoagulation ◽  
The Mean ◽  
Diode Laser Cyclophotocoagulation

Purpose: To assess the efficacy and safety of a standardized micropulse transscleral diode laser cyclophotocoagulation procedure in refractory glaucoma. Methods: Retrospective, interventional study in a series of 37 consecutive patients with refractory glaucoma, cyclodestructive procedure-naive, who underwent micropulse transscleral diode laser cyclophotocoagulation from December 2016 to October 2017. A successful laser treatment was defined as (1) intraocular pressure between 6 and 18 mm Hg; (2) 20% of baseline intraocular pressure reduction; (3) no additional glaucoma medications; (4) no decrease in vision due to complications or change in intraocular pressure; and (5) no need for additional glaucoma surgery except micropulse transscleral diode laser cyclophotocoagulation retreatment. Results: Mean age was 60.2 years. Mean follow-up was 9.7 ± 3.9 months. The mean preoperative intraocular pressure (28.7 mm Hg) significantly decreased to 21.0 mm Hg at 1 month, 18.5 mm Hg at 3 months, 18.4 mm Hg at 6 months, and 18.5 mm Hg at 12 months ( p < 0.01 at all time points). The mean number of preoperative glaucoma medications (4.7) decreased to 4.0 at 1 month ( p = 0.14), 4.5 at 3 months ( p < 0.05), 3.9 at 6 months ( p < 0.05), and 3.6 at 12 months ( p < 0.05). At 1 year, the success rate was 35% with a mean intraocular pressure lowering of 36%. One patient had hypotony and a loss of best-corrected visual acuity. Mild transient postoperative inflammation was observed in 8% of the cases. Conclusion: Using a standardized procedure, micropulse transscleral diode laser cyclophotocoagulation allows a mild intraocular pressure decrease with a low rate of complications and thus achieves a relatively good profit risk benefit, mostly for moderately hypertensive refractory glaucoma.

Trans-scleral diode laser cyclophotocoagulation for refractory glaucoma after high-risk penetrating keratoplasty

2015 ◽  
Vol 36 (3) ◽  
pp. 373-383 ◽  
Author(s):  
Alejandro Rodríguez-García ◽  
Luis Alonso González-González ◽  
J. Carlos Alvarez-Guzmán
Keyword(s):  
High Risk ◽  
Diode Laser ◽  
Penetrating Keratoplasty ◽  
Refractory Glaucoma ◽  
Diode Laser Cyclophotocoagulation

scholarly journals Effect of diode laser cyclophotocoagulation in treatment of patients with refractory glaucoma

2015 ◽  
Vol 72 (1) ◽  
pp. 16-20 ◽  
Author(s):  
Vladimir Canadanovic ◽  
Ljiljana Tusek-Ljesevic ◽  
Aleksandar Miljkovic ◽  
Sava Barisic ◽  
Tatjana Bedov ◽  
...  
Keyword(s):  
Diode Laser ◽  
Panretinal Photocoagulation ◽  
Safe Procedure ◽  
Refractory Glaucoma ◽  
Group I ◽  
Clinical Center ◽  
The Mean ◽  
Group Ii ◽  
Novi Sad ◽  
Diode Laser Cyclophotocoagulation

Background/Aim. Refractory glaucoma is glaucoma resistant to conventional management (maximally tolerated medical therapy, one or more glaucoma surgeries) and glaucoma in cases of neovascularisation after panretinal photocoagulation or cryoablation. The aim of the study was to determine the intraocular pressure (IOP) lowering efficacy of transscleral diode laser cyclophotocoagulation (DCPC) treatment in the management of pain and IOP in patients with refractory glaucoma. Methods. This nonrandomized, retrospective study, included 95 patients (95 eyes) with refractory glaucoma treated at the University Eye Clinic, Clinical Center of Vojvodina, Novi Sad, Serbia, between November 2007 and November 2012 in accordance with the established protocols (16-18 spots, 270?, up to 5J of energy). All the eyes were treated with transscleral DCPC (Iris Medical OcuLight SLx, Iridex Co, Mountain View, USA). Patient's symptoms, bests corrected visual acuity and IOP were recorded 7 days, and 1, 3 and 6 months after the DCPC treatment. Results. Out of 95 patients (95 eyes) enrolled in this study 24 (25.2%) were with primary (the group I), and 71 (74.5%) with secondary (the group II) glaucoma. The mean baseline IOP in these two groups was similar: 36.08 ? 8.39 mmHg for the first group and 37.36 ? 8.19 mmHg in the second group. Measurement of the mean IOP in the group I showed the following results: on the day 7 it was 13.96 ? 8.30 mmHg (62.1% decrease of the baseline value), on the day 30 it was 18.44 ? 8.85 mmHg (48.9% decrease regarding the baseline value), after 3 months it was 22.44 ? 7.36 mmHg (37.8% decrease regarding the baseline value), and after 6 months it was 25.92 ? 7.65 mmHg (28.2% decrease regarding the baseline value). Measurement of IOP in the group II showed the following results: on the day 7 it was 15.77 ? 9.73 mmHg (57.8% decrease of the baseline value), on the day 30 it was 20.14 ? 10.20 mmHg (46.1% decrease regarding the baseline value), after 3 months it was 23.46 ? 9.83 mmHg (37.2% decrease regarding the baseline value) and after 6 months it was 27.23 ? 9.87 mmHg (27.2% decrease regarding the baseline value). Pain was the main symptom in 70 (73.6%) patients before the treatment and it persisted in only 4 (4.2%) of our patients. Other complaints (burning, stinging, foreign body sensation) were experienced by 39 (41%) of the patients, postoperatively. A total of 52 (54.7%) patients had no complaints after the treatment. Conclusion. Our study confirmed that transscleral DCPC is a useful, effective and safe procedure with predictable amount of IOP decrease, which makes it the treatment of choice for refractory glaucoma.

Sign in / Sign up

Export Citation Format

Share Document